News & Events

Published On: 8/24/2020

TARGET-NASH Expands to Europe, Enrolls First Participant

Target RWE, an innovative health evidence solutions company generating real-world evidence (RWE) and delivering regulatory-grade data to partners to advance clinical, medical, and commercial outcomes, has announced its nonalcoholic steatohepatitis (NASH) longitudinal study, TARGET-NASH, has enrolled its first European patient.

“Our TARGET-NASH study continues to grow and lead real-world evidence generation in NASH. TARGET-NASH enrolling its first European patient is an important step forward and will provide important perspectives for our key stakeholders on this growing health concern,” said Target RWE CEO Neal Bibeau.

Launched in 2016, TARGET-NASH is an observational study of more than 5,000 participants diagnosed with nonalcoholic fatty liver disease (NAFLD).  Target RWE’s network of sites includes both community and academic centers and enrolls adult and pediatric participants across the spectrum of this liver disease. Once enrolled, three years of retrospective data and five years of prospective data is collected from TARGET-NASH participants, including Patient-Reported Outcomes (PRO) and biorepository samples.

The TARGET-NASH dataset is critical to providing a baseline and measuring the impact of current practice guidelines, management, and new therapies utilized for patients with medical co-morbidities, hepatic, cardiovascular, and/or other endocrine-associated outcomes.

TARGET-NASH was the first study established by Target RWE when the company was created in 2015. Target RWE has added seven additional studies to its portfolio since then including: hepatocellular carcinoma (HCC), inflammatory bowel disease (IBD), primary biliary cholangitis (PBC), immune-mediated inflammatory skin conditions (DERM), chronic hepatitis B (HBV), asthma, and COVID-19.